Hrt Financial LP Insmed Inc Transaction History

Hrt Financial LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$25.72 - $29.94 $2.1 Million - $2.45 Million	-81,791 Reduced 76.63%	24,944 $676,000
Q4 2023 Feb 09, 2024	BUY	$23.42 - $31.74 $2.5 Million - $3.39 Million	106,735 New	106,735 $3.31 Million
Q2 2023 Aug 11, 2023	BUY	$16.44 - $21.1 $238,725 - $306,393	14,521 New	14,521 $306,000
Q3 2022 Nov 14, 2022	SELL	$20.88 - $28.21 $398,098 - $537,851	-19,066 Reduced 35.97%	33,945 $731,000
Q2 2022 Aug 12, 2022	BUY	$17.07 - $25.71 $722,863 - $1.09 Million	42,347 Added 397.1%	53,011 $1.05 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $217,758 - $299,978	10,664 New	10,664 $250,000
Q4 2020 Feb 16, 2021	SELL	$31.45 - $40.54 $1.2 Million - $1.54 Million	-38,036 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$26.0 - $34.5 $988,936 - $1.31 Million	38,036 New	38,036 $1.22 Million
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $221,146 - $551,325	-16,225 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$16.12 - $24.98 $261,547 - $405,300	16,225 New	16,225 $387,000

447

170M

5.79M

5.18M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.89B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.